Helicobacter pylori infection
Conditions
Interventions
Experimental group A:VPZ 20 mg 2/day and Amoxicillin 1000mg 3/day for 7 days
Experimental group B:VPZ 20 mg 2/day and Amoxicillin 750mg 4/day for 7 days
Experimental group C:VPZ 20 mg 2/day and Amoxicillin 1000mg 3/day for 10 days
Experimental group D:VPZ 20 mg 2/day and Amoxicillin 750mg 4/day for 10 days
Sponsors
Jiangsu Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. Chronic gastritis confirmed HP(+) by gastroscopy within three months, and patients who met the indications of recommended eradication of Helicobacter pylori in the Sixth National Consensus Report on the Treatment of Helicobacter Pylori Infection; 3. H. pylori (+) determined by C13 or C14; 4. Treatment-naive patients for eradication of H. pylori infection. 5. Signed informed consent
Exclusion criteria
Exclusion criteria: 1. Allergy to medications used in this clinical trial; 2. Use of vonoprazan,PPI, histamine H2-receptor antagonists, antibiotics, bismuth, or probiotics 1 months before initiating study treatment; 3.Female patients planning pregnancy, as well as pregnant and breastfeeding patients; 4. Use of adrenocorticosteroids, nonsteroidal anti-inflammatory drugs, and anticoagulants; 5. Presence of diseases or clinical conditions, such as cardiac vascular disease,lung disease, liver disease,kidney disease, metabolic disease, mental illness, or malignant tumors, that might interfere with the evaluation of study treatment; 6. Previous esophageal or stomach surgical procedures; 7. Incomplete follow-up or noncompliance with the study treatment;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient compliance;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactZhang Guoxin
Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University
Outcome results
None listed